Table 3.
Linear mixed modeling estimates of HNEC ROS inhibition and migration time for each treatment, relative to untreated scratched controls.
| Treatment | ROS activity compared to controls | Migration rate | p < 0.05 |
|---|---|---|---|
| HUMAN NASAL EPITHELIAL CELLS | |||
| Mitoquinone | −0.376 | 0.072 | * |
| Linezolid | −0.345 | 0.091 | * |
| Clindamycin | −0.216 | 0.168 | * |
| Erythromycin | −0.171 | 0.128 | * |
| Ciprofloxacin | −0.152 | 0.056 | * |
| Tedizolid | −0.134 | 0.205 | * |
| Roxithromycin | −0.127 | 0.196 | * |
| Azithromycin | −0.112 | 0.090 | |
| Augmentin | −0.087 | 0.185 | |
| Clarithromycin | −0.071 | 0.183 | |
| Mupirocin | −0.030 | 0.094 | * |
| Doxycycline | 0.006 | 0.064 | |
P-values indicate a significant relationship between the two for the given treatment
(*
p < 0.05). Values and treatments sorted by inhibition of ROS activity. Treatments in bold also showed a significant reduction in wound closure time compared to untreated wounds.